



March 1, 2016

## Threshold Pharmaceuticals Announces Presentation and Webcast at the Cowen and Company 36th Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., March 01, 2016 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the Cowen and Company 36th Annual Health Care Conference on March 8, 2016, at 9:20 a.m. Eastern Time.

A live webcast of the presentation will be available under "Webcasts" in the Investors section of [www.thresholdpharm.com](http://www.thresholdpharm.com). A replay of the presentation will be archived on the site for 30 days.

### About Threshold Pharmaceuticals

Threshold Pharmaceuticals, Inc. is a biotechnology company focused on the development of drugs targeting tumor hypoxia, the low oxygen condition found in the microenvironments of most solid tumors, as well as the bone marrows of some patients with hematologic malignancies. This approach offers broad potential to treat a variety of cancers. By selectively targeting tumor cells, we have a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs. For additional information, please visit our website ([www.thresholdpharm.com](http://www.thresholdpharm.com)).

### Forward-Looking Statements

Except for statements of historical fact, the statements in this press release are forward-looking statements, including statements regarding the potential therapeutic uses and benefits of its drug candidates. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to: Threshold's need for and the availability of resources to develop its drug candidates and to support Threshold's operations including the expense required to conduct clinical trials and analyze data; issues arising in the regulatory or manufacturing process and the results of such clinical trials (including product safety issues and efficacy results). Further information regarding these and other risks is included under the heading "Risk Factors" in Threshold's Quarterly Report on Form 10-Q, which has been filed with the Securities and Exchange Commission on November 2, 2015 and is available from the SEC's website ([www.sec.gov](http://www.sec.gov)) and on our website ([www.thresholdpharm.com](http://www.thresholdpharm.com)) under the heading "Investors." We undertake no duty to update any forward-looking statement made in this news release.

Contact

Mark Hopkins, Ph.D., J.D.

Vice President of Intellectual Property and Assistant General Counsel

Phone: 650-474-8213

E-mail: [mhopkins@thresholdpharm.com](mailto:mhopkins@thresholdpharm.com)

 [Primary Logo](#)

Source: Threshold Pharmaceuticals, Inc.

News Provided by Acquire Media